Ann: Agreement with In2pharma & expansion of Health Product range, page-4

Not concerned with the company being slept on at the moment to be honest. Happy to sit and accumulate and wait for the market to catch on.

Have no doubt that this stock will command more attention in the coming months as we are coming into a period of significant development - phase I trials, cannabis prodcuts being imported, more brands being launched/added and assume this will underpin more revenue growth. Consider this cheeap and an opportunity.

Good luck and DYOR.